Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

NCT02092324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Neutrophilic Leukemia

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Ruxolitinib Phosphate

Sponsor

OHSU Knight Cancer Institute